I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma

Sponsor
Xuzhou Central Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04779788
Collaborator
(none)
100
1
2
14.9
6.7

Study Details

Study Description

Brief Summary

Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative stent insertion is the only treatment option available for most patients. At present, I-125 seeds loaded stent has been developed to improve the stent patency and patients' survival. Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.

Condition or Disease Intervention/Treatment Phase
  • Device: I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
  • Device: Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
N/A

Detailed Description

Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative interventions are the only treatment option available for most patients. Of the available palliative treatments, percutaneous or endoscopic stent insertion is the most frequently used to treat malignant biliary obstruction patients.

Although stent insertion can achieve the good short-term outcomes for patients with malignant biliary obstruction, stent dysfunction remains a common outcome in these treated patients, limiting the long-term efficacy of this treatment strategy. In order to overcome this shortcoming of the normal stent insertion, many researchers have developed a novel biliary I-125 seeds loaded stent. The I-125 seeds loaded stents not only can effectively relieve the jaundice, but also can provide the brachytherapy to the tumor. Previous meta-analyses also indicated that showed that relative to normal stent insertion, I-125 seeds loaded stent insertion was associated with longer survival and stent patency in inoperable malignant biliary obstruction patients. However, most previous studies included malignant biliary obstruction patients with different cancer types and malignant biliary obstruction sites, and therefore, the risk of bias did exist. Therefore, there is a clear need for a study comparing these two stent types in patients with a single type of cancer.

Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma
Actual Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: I-125 seeds loaded stent group

Patients who receive the I-125 seeds loaded stent insertion

Device: I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent

Active Comparator: Normal stent group

Patients who receive the normal stent insertion

Device: Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
Bare self-expanded metal stent

Outcome Measures

Primary Outcome Measures

  1. Overall survival [From the date of randomization until the date of first documented death from any cause, assessed up to 12 months]

    From the date of randomization until the date of first documented death from any cause.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients with a diagnosed hilar Cholangiocarcinoma; Inoperable cases; Patients showed evidence of obstructive jaundice; Eastern Cooperative Oncology Group performance status < 4.

Exclusion Criteria:

Patients who underwent post-operative external radiotherapy; Patients in whom prior biliary stent insertion or drainage were performed; Patients suffering from serious dysfunction of the pulmonary, renal, cardiac, or coagulatory systems.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xuzhou Central Hospital Xuzhou Jiangsu China 221009

Sponsors and Collaborators

  • Xuzhou Central Hospital

Investigators

  • Principal Investigator: Xian-Chi Li, MD, Xuzhou Central Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Xuzhou Central Hospital
ClinicalTrials.gov Identifier:
NCT04779788
Other Study ID Numbers:
  • 20210218015
First Posted:
Mar 3, 2021
Last Update Posted:
Jul 14, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 14, 2021